Lv1
64 积分 2023-12-27 加入
Anti CD161 Antibody IMT-009 Is a Novel Immunotherapeutic Agent That Effectively Blocks the Inhibitory CLEC2D/CD161 Axis in CLEC2D+ B Cell Hematological Malignancies Reinvigorating T and NK Cell Function Leading to Anti-Tumor Benefit
7天前
已关闭
Interplay between CD28 and PD-1 in T cell immunotherapy
7天前
已关闭
A novel inhalable nanobody targeting IL-4Rα for the treatment of asthma
1个月前
已完结
C8Mab-2: An Anti-Mouse C–C Motif Chemokine Receptor 8 Monoclonal Antibody for Immunocytochemistry
1个月前
已完结
CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells
1个月前
已完结
Efficacy and safety of ziresovir in hospitalised infants aged 6 months or younger with respiratory syncytial virus infection in China: findings from a phase 3 randomised trial with 24-month follow-up
2个月前
已完结
Functional DKK1 antibodies demonstrate antagonistic and tumor suppression activities
3个月前
已完结
Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity
4个月前
已完结
Physiologically‐Based Pharmacokinetic Modeling of Omalizumab to Predict the Pharmacokinetics and Pharmacodynamics in Pediatric Patients
4个月前
已完结
CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies
4个月前
已完结
皖公网安备34019202002308
